MedTrace Logo

Effect of New Topical Preparation for Treatment of Acne Vulgaris

NCT05899699 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-06-13

No results posted yet for this study

Summary

The investigators propose a randomized, double-blind control trial study to evaluate the efficacy and safety of the optimized topical combination ME of the investigated drugs in the treatment of acne vulgaris containing DAP-FLU in comparison with standard therapy of Adapalene at Mansoura University Dermatology and Andrology Outpatient Clinic.

Conditions

  • Acne Vulgaris

Interventions

DRUG

DAP-FLU ME

Combination therapy of topical anti-inflammatory agent (Dapsone 5%) and anti-androgenic agent (Flutamide 2.5%) with anti-bacterial agent of micro-emulsion component (tea tree oil 5%)

DRUG

Adapalene .1% gel

Adapalene .1% gel

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Amgad El-Sayed Salem · Mansoura University

  • Elham A. Mohamed · Mansoura University

  • Noha M. Saleh · Mansoura University

  • Marwa Z. Mubarak · Mansoura University

  • Galal M. Abdelghania · Mansoura University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-05
Primary Completion
2023-09-01
Completion
2023-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05899699 on ClinicalTrials.gov